8-(trifluoromethoxy)chroman-4-one | 276697-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 8-(trifluoromethoxy)chroman-4-one
• 英文别名: 8-(trifluoromethoxy)-2,3-dihydrochromen-4-one
• CAS: 276697-79-1
• 化学式: C₁₀H₇F₃O₃
• 分子量: 232.159
• InChiKey: NVTWXGBPZHFELL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-(trifluoromethoxy)chroman-4-one 在 吡啶 、 palladium 10% on activated carbon 、 氨 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 25.0h， 生成 8-(Trifluoromethoxy)chromane-4-ylamine
  参考文献：
  名称：

  Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

  摘要：

  Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.056
• 作为产物：
  描述：

  1-(3-chloroprop-2-ynyloxy)-2-(trifluoromethoxy)benzene 在 水 作用下， 以 乙二醇 为溶剂， 反应 25.0h， 生成 8-(trifluoromethoxy)chroman-4-one
  参考文献：
  名称：

  [EN] TRPV1 ANTAGONISTS
  [FR] ANTAGONISTES DE TRPV1

  摘要：

  本文披露了式（I）的化合物，或其药用可接受的盐、溶剂化合物、前药、前药的盐或它们的组合，其中R1、R2、R3、R4和m在规范中有定义。还披露了包含这种化合物的组合物以及使用这种化合物和组合物治疗疾病和疾病的方法。

  公开号：

  WO2010045402A1

文献信息

• Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
  申请人：Gomtsyan Arthur

  公开号：US20060128689A1

  公开（公告）日：2006-06-15

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  对VR1受体拮抗剂，其化学式为(I)或其药用可接受的盐、前药或前药的盐，其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m的定义如本文所述，并且在通过抑制VR1受体预防或改善的疾病中具有用处。
• [EN] TRPV1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV1
  申请人：ABBOTT LAB

  公开号：WO2010045401A1

  公开（公告）日：2010-04-22

  Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文披露了式（I）的化合物，或其药用可接受的盐、溶剂化合物、前药、前药的盐或它们的组合，其中R1、R2、R3、R4和m在规范中有定义。还披露了包含这种化合物的组合物以及使用这种化合物和组合物治疗疾病和疾病的方法。
• New amidino derivatives and their use as thrombin inhibitors
  申请人：AstraZeneca AB

  公开号：US20040186090A1

  公开（公告）日：2004-09-23

  There is provided compounds of formula I 1 wherein R 1 , R x , Y, R y , n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了I1式化合物，其中R1、Rx、Y、Ry、n和B的含义如描述中所示，可用作竞争性蛋白酶抑制剂，例如凝血酶，特别是在需要抑制凝血酶的情况下（例如血栓形成）或作为抗凝剂的治疗。
• Amidino derivatives and their use as thrombin inhibitors
  申请人：AstraZeneca AB

  公开号：US07241757B2

  公开（公告）日：2007-07-10

  There is provided compounds of formula I wherein R1, Rx, Y, Ry, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了I式化合物，其中R1、Rx、Y、Ry、n和B的含义如描述中所述，可用作竞争性蛋白酶抑制剂，例如凝血酶，特别适用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• TRPV1 ANTAGONISTS
  申请人：Gomtsyan Arthur R.

  公开号：US20100120846A1

  公开（公告）日：2010-05-13

  Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , R 4 , and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了式(I)的化合物，或其药学上可接受的盐、溶剂、前药盐、前药的盐或其组合物，其中R1、R2、R3、R4和m在规范中被定义。还揭示了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和病症的方法。